Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?
The consensus price target hints at a 38.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Si-Bone (SIBN) delivered earnings and revenue surprises of +40.00% and +1.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Bears are Losing Control Over Si-Bone (SIBN), Here's Why It's a 'Buy' Now
Si-Bone (SIBN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks
Wall Street Analysts Predict a 71.13% Upside in Si-Bone (SIBN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 71.1% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
How Much Upside is Left in Si-Bone (SIBN)? Wall Street Analysts Think 65.27%
The consensus price target hints at a 65.3% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Why Si-Bone Stock Soared by Almost 20% on Tuesday
Key PointsIt posted rather encouraging first-quarter results...
Si-Bone (SIBN) delivered earnings and revenue surprises of +41.18% and +2.46%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Tops Q1 Earnings and Revenue Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of +22.07% and +4.04%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Avanos Medical (AVNS) Lags Q1 Earnings Estimates
Avanos Medical (AVNS) delivered earnings and revenue surprises of -4.35% and +7.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?